Tech Transfer Deals, July 2016: Kite Moves Toward Off-The-Shelf T-Cell Therapy

15 Aug 2016

• By Joseph Haas

Kite licenses allogeneic cell technology from UCLA that may enable it to create off-the-shelf T-cell therapeutics, augmenting its ongoing development of autologous cancer therapies. See Scrip's monthly update on licensing agreements between companies and universities or other research institutions.

Kite Pharma Inc. recently told investors that it's on the cusp of producing late-stage data that could enable a filing of its lead cancer immunotherapy candidate, KTE-C19, but the biotech also recently made a move toward producing off-the-shelf T-cell cancer therapies under a technology licensing deal with University of California, Los Angeles.

On July 25, Kite licensed exclusive global rights to allogeneic T-cell technology intellectual property from UCLA that could enable it to develop T-cell therapeutics for cancer from renewable pluripotent

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

08 May 2025

• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

06 May 2025

• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.